Literature DB >> 20949305

Prediction of malignancy grading using computed tomography perfusion imaging in nonenhancing supratentorial gliomas.

Takaaki Beppu1, Makoto Sasaki, Kohsuke Kudo, Akira Kurose, Masaru Takeda, Hiroshi Kashimura, Akira Ogawa, Kuniaki Ogasawara.   

Abstract

Tumor grade differentiation is often difficult using routine neuroimaging alone. Computed tomography perfusion imaging (CTP) provides quantitative information on tumor vasculature that closely parallels the degree of tumor malignancy. This study examined whether CTP is useful for preoperatively predicting the grade of malignancy in glioma showing no enhancement on contrast-enhanced magnetic resonance imaging (MRI). Subjects comprised 17 patients with supratentorial glioma without enhancement on MRI. CTP was performed preoperatively, and absolute values and normalized ratios of parameters were calculated. Postoperatively, subjects were classified into two groups according to histological diagnosis of grade 3 (G3) glioma or grade 2 (G2) glioma. Absolute values and normalized ratios for each parameter were compared between G3 and G2. Accuracies of normalized ratios for cerebral blood flow (nCBF) and cerebral blood volume (nCBV) in predicting a diagnosis of G3 were assessed. In addition, nCBV was compared between diffuse astrocytoma, G2 oligodendroglial tumor (OT), and G3 OT. Values for nCBF and nCBV differed significantly between G3 and G2. Using nCBV of 1.6 as a cutoff, specificity and sensitivity for distinguishing G3 were 83.3% and 90.9%, respectively. No significant difference in nCBV was seen between diffuse astrocytoma and G2 OT, whereas differences were noted between G2 and G3 OTs, and between diffuse astrocytoma and G3 OT. CTP offers a useful method for differentiating between G3 and G2 in nonenhancing gliomas.

Entities:  

Mesh:

Year:  2010        PMID: 20949305     DOI: 10.1007/s11060-010-0433-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  33 in total

1.  Cerebral blood flow, blood volume, and vascular permeability of cerebral glioma assessed with dynamic CT perfusion imaging.

Authors:  J D Eastwood; J M Provenzale
Journal:  Neuroradiology       Date:  2003-04-29       Impact factor: 2.804

2.  Quantitative cerebral blood flow measurement with dynamic perfusion CT using the vascular-pixel elimination method: comparison with H2(15)O positron emission tomography.

Authors:  Kohsuke Kudo; Satoshi Terae; Chietsugu Katoh; Masaki Oka; Tohru Shiga; Nagara Tamaki; Kazuo Miyasaka
Journal:  AJNR Am J Neuroradiol       Date:  2003-03       Impact factor: 3.825

3.  Perfusion CT with iodinated contrast material.

Authors:  James D Eastwood; Michael H Lev; James M Provenzale
Journal:  AJR Am J Roentgenol       Date:  2003-01       Impact factor: 3.959

4.  Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion-weighted magnetic resonance imaging.

Authors:  Antonio C M Maia; Suzana M F Malheiros; Antonio J da Rocha; João N Stávale; Iara F Guimarães; Lia R R Borges; Adrialdo J Santos; Carlos J da Silva; Julieta G S P de Melo; Oreste P Lanzoni; Alberto A Gabbai; Fernando A P Ferraz
Journal:  J Neurosurg       Date:  2004-12       Impact factor: 5.115

5.  Comparison of cerebral blood volume and permeability in preoperative grading of intracranial glioma using CT perfusion imaging.

Authors:  Bei Ding; Hua Wei Ling; Ke Min Chen; Hong Jiang; Yan Bo Zhu
Journal:  Neuroradiology       Date:  2006-08-26       Impact factor: 2.804

6.  First-pass perfusion computed tomography: initial experience in differentiating recurrent brain tumors from radiation effects and radiation necrosis.

Authors:  Rajan Jain; Lisa Scarpace; Shehanaz Ellika; Lonni R Schultz; Jack P Rock; Mark L Rosenblum; Suresh C Patel; Ting-Yim Lee; Tom Mikkelsen
Journal:  Neurosurgery       Date:  2007-10       Impact factor: 4.654

7.  Quantitative estimation of permeability surface-area product in astroglial brain tumors using perfusion CT and correlation with histopathologic grade.

Authors:  R Jain; S K Ellika; L Scarpace; L R Schultz; J P Rock; J Gutierrez; S C Patel; J Ewing; T Mikkelsen
Journal:  AJNR Am J Neuroradiol       Date:  2008-01-17       Impact factor: 3.825

8.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].

Authors:  Michael H Lev; Yelda Ozsunar; John W Henson; Amjad A Rasheed; Glenn D Barest; Griffith R Harsh; Markus M Fitzek; E Antonio Chiocca; James D Rabinov; Andrew N Csavoy; Bruce R Rosen; Fred H Hochberg; Pamela W Schaefer; R Gilberto Gonzalez
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

9.  Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation?

Authors:  Nasuda Danchaivijitr; Adam D Waldman; Daniel J Tozer; Christopher E Benton; Gisele Brasil Caseiras; Paul S Tofts; Jeremy H Rees; H Rolf Jäger
Journal:  Radiology       Date:  2008-04       Impact factor: 11.105

Review 10.  Advances in imaging low-grade gliomas.

Authors:  Stephen J Price
Journal:  Adv Tech Stand Neurosurg       Date:  2010
View more
  3 in total

1.  Diagnostic Performance of Arterial Spin Labeling for Grading Nonenhancing Astrocytic Tumors.

Authors:  Delgerdalai Khashbat; Masafumi Harada; Takashi Abe; Mungunbagana Ganbold; Seiji Iwamoto; Naoto Uyama; Saho Irahara; Youichi Otomi; Teruyoshi Kageji; Shinji Nagahiro
Journal:  Magn Reson Med Sci       Date:  2017-12-12       Impact factor: 2.471

2.  Prediction of malignant glioma grades using contrast-enhanced T1-weighted and T2-weighted magnetic resonance images based on a radiomic analysis.

Authors:  Takahiro Nakamoto; Wataru Takahashi; Akihiro Haga; Satoshi Takahashi; Shigeru Kiryu; Kanabu Nawa; Takeshi Ohta; Sho Ozaki; Yuki Nozawa; Shota Tanaka; Akitake Mukasa; Keiichi Nakagawa
Journal:  Sci Rep       Date:  2019-12-19       Impact factor: 4.379

3.  The Value of H2BC12 for Predicting Poor Survival Outcomes in Patients With WHO Grade II and III Gliomas.

Authors:  Jie Zhou; Zhaoquan Xing; Yilei Xiao; Mengyou Li; Xin Li; Ding Wang; Zhaogang Dong
Journal:  Front Mol Biosci       Date:  2022-04-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.